Q-omics provides the consensus-scored TBX18 profile across patient tissues and cancer cell-line models. TBX18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TBX18 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TBX18 RNA expression shows 16,699 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where TBX18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX18 survival associations across molecular data types. TBX18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX18 RNA expression–survival associations across cancer types. High TBX18 expression shows unfavorable associations in KIRP, UVM, ACC, STAD, MESO and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TBX18 RNA expression.
This table summarizes TBX18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBX18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX18 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in HNSC, UCEC and LUSC. The HNSC box plot shows higher TBX18 RNA expression in tumor versus normal tissue (log2 FC = +2.050, t-test p < 0.001).
This table shows molecular features associated with TBX18 in patient tissues and cancer cell lines. In patient samples, TBX18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
